RaQualia Pharma Inc.-Product Pipeline Review-2015

RaQualia Pharma Inc.-Product Pipeline Review-2015

  • Products Id :- GMDHC07409CDB
  • |
  • Pages: 42
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

RaQualia Pharma Inc.-Product Pipeline Review-2015


Global Markets Direct's, 'RaQualia Pharma Inc.-Product Pipeline Review-2015', provides an overview of the RaQualia Pharma Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of RaQualia Pharma Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides brief overview of RaQualia Pharma Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of RaQualia Pharma Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the RaQualia Pharma Inc.'s pipeline products

Reasons To Buy

Evaluate RaQualia Pharma Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of RaQualia Pharma Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the RaQualia Pharma Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of RaQualia Pharma Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of RaQualia Pharma Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of RaQualia Pharma Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

RaQualia Pharma Inc. Snapshot 6

RaQualia Pharma Inc. Overview 6

Key Information 6

Key Facts 6

RaQualia Pharma Inc.-Research and Development Overview 7

Key Therapeutic Areas 7

RaQualia Pharma Inc.-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Out-Licensed Products 12

Out-Licensed Products/Combination Treatment Modalities 13

RaQualia Pharma Inc.-Pipeline Products Glance 14

RaQualia Pharma Inc.-Late Stage Pipeline Products 14

Phase III Products/Combination Treatment Modalities 14

RaQualia Pharma Inc.-Clinical Stage Pipeline Products 15

Phase I Products/Combination Treatment Modalities 15

RaQualia Pharma Inc.-Early Stage Pipeline Products 16

Preclinical Products/Combination Treatment Modalities 16

Discovery Products/Combination Treatment Modalities 17

RaQualia Pharma Inc.-Drug Profiles 18

RQ-00000004 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

RQ-00000010 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

RQ-00000774 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

RQ-00201894 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

RQ-00202730 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

RQ-00203066 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

RQ-00310941 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

RQ-00432933 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Small Molecule to Block Cav3.2 for Neuropathic Pain 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Small Molecules to Block Nav1.7 Sodium Channel for Pain 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Small Molecules to Block Nav1.8 Sodium Channel for Pain 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Small Molecules to Block TRPM8 for Neuropathic Pain 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Small Molecule to Modulate Specific Ion Channel for an Undisclosed Indication 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Small Molecule to Modulate Specific Ion Channel for Pain 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

RaQualia Pharma Inc.-Pipeline Analysis 32

RaQualia Pharma Inc.-Pipeline Products by Target 32

RaQualia Pharma Inc.-Pipeline Products by Route of Administration 33

RaQualia Pharma Inc.-Pipeline Products by Molecule Type 34

RaQualia Pharma Inc.-Pipeline Products by Mechanism of Action 35

RaQualia Pharma Inc.-Recent Pipeline Updates 36

RaQualia Pharma Inc.-Dormant Projects 39

RaQualia Pharma Inc.-Locations And Subsidiaries 40

Head Office 40

Other Locations & Subsidiaries 40

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 41

Disclaimer 42

List of Tables

RaQualia Pharma Inc., Key Information 6

RaQualia Pharma Inc., Key Facts 6

RaQualia Pharma Inc.-Pipeline by Indication, 2015 8

RaQualia Pharma Inc.-Pipeline by Stage of Development, 2015 10

RaQualia Pharma Inc.-Monotherapy Products in Pipeline, 2015 11

RaQualia Pharma Inc.-Out-Licensed Products in Pipeline, 2015 12

RaQualia Pharma Inc.-Out-Licensed Products/ Combination Treatment Modalities, 2015 13

RaQualia Pharma Inc.-Phase III, 2015 14

RaQualia Pharma Inc.-Phase I, 2015 15

RaQualia Pharma Inc.-Preclinical, 2015 16

RaQualia Pharma Inc.-Discovery, 2015 17

RaQualia Pharma Inc.-Pipeline by Target, 2015 32

RaQualia Pharma Inc.-Pipeline by Route of Administration, 2015 33

RaQualia Pharma Inc.-Pipeline by Molecule Type, 2015 34

RaQualia Pharma Inc.-Pipeline Products by Mechanism of Action, 2015 35

RaQualia Pharma Inc.-Recent Pipeline Updates, 2015 36

RaQualia Pharma Inc.-Dormant Developmental Projects,2015 39

RaQualia Pharma Inc., Other Locations 40

RaQualia Pharma Inc., Subsidiaries 40

List of Figures

RaQualia Pharma Inc.-Pipeline by Top 10 Indication, 2015 8

RaQualia Pharma Inc.-Pipeline by Stage of Development, 2015 10

RaQualia Pharma Inc.-Monotherapy Products in Pipeline, 2015 11

RaQualia Pharma Inc.-Pipeline by Top 10 Target, 2015 32

RaQualia Pharma Inc.-Pipeline by Top 10 Route of Administration, 2015 33

RaQualia Pharma Inc.-Pipeline by Top 10 Molecule Type, 2015 34

RaQualia Pharma Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Current R&D Portfolio of RaQualia Pharma Inc.; RaQualia Pharma Inc. - Key Therapeutics; RaQualia Pharma Inc. - Pipeline Overview and Promising Molecules; RaQualia Pharma Inc. - News; RaQualia Pharma Inc. - Latest Updates; RaQualia Pharma Inc. - Pipeline; RaQualia Pharma Inc. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 102105
Site License
USD 3000 INR 204210
Corporate User License
USD 4500 INR 306315



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com